Uncertainty and choice: The challenges of pharmaceutical efficacy, safety, and cost

Managerial and Decision Economics

Volumn 28, Issue 4-5, 2007, Pages 267-283

  Scherer, F M ^a,b  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34548307206     PISSN: 01436570     EISSN: 10991468     Source Type: Journal    
DOI: 10.1002/mde.1340     Document Type: Article

References (23)

1. Angell MM. 2004. The Truth About the Drug Companies. Random House: New York.
2. Baumol WJ, Blackman SAB, Wolff E. 1989. Productivity and American Leadership: The Long View. MIT Press: Cambridge.
3. Binswanger H, Ruttan V. 1978. Induced Innovation. Johns Hopkins University Press: Baltimore.
4. DiMasi JA. 2000. New drug innovation and pharmaceutical industry structure: trends in the output of pharmaceutical firms. Drug Information Journal 34: 1169-1194.
5. Grabowski HG, Vernon JM. 1990. A new look at the returns and risks to pharmaceutical R&D. Management Science 36: 804-821.
6. Grabowski HG, diMasi J, Hansen R. 2003. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22: 151-185.
7. Lanjouw JO. 2005. Patents, price controls and access to new drugs: how policy affects global market entry. Working Paper, University of California Berkeley, April 19, 2005.
8. Love J. 2003. Evidence regarding research and development investments in innovative and non-innovative medicines. Working Paper, Consumer Project on Technology, Washington.
9. Madden BJ. 2004. Breaking the FDA monopoly. Regulation Summer 2004, 20: 64-66.
10. National Institute for Health Care Management. 2002. Changing Patterns of Pharmaceutical Innovation. Washington.
11. Newhouse JP. 1992. Medical care costs: how much welfare loss? Journal of Economic Perspectives 6: 11-16.
12. Okie S. What ails the FDA?: perspective. 2005. New England Journal of Medicine March: 1063-1066.
13. Peltzman S. 1987. The health effects of mandatory prescriptions. Journal of Law and Economics 30: 207-238.
14. Scherer FM. 1996. Industry Structure, Strategy, and Public Policy. HarperCollins: New York.
15. Scherer FM. 1999. New Perspectives on Economic Growth and Technological Innovation. Brookings Institution: Washington.
16. Scherer FM. 1999. The pharmaceutical industry. In Handbook of Health Economics, Culyer AJ, Newhouse JP (eds), vol. IB. Elsevier: Amsterdam.
17. Scherer FM. 2001. The link between gross profitability and pharmaceutical R&D spending. Health Affairs 20: 216-220.
18. Scherer FM. 2004. The pharmaceutical industry-prices and progress. New England Journal of Medicine August 26, 2004, 351: 927-932.
19. Scherer FM, Harhoff D. 2000. Technology policy for a world of skew-distributed outcomes. Research Policy 29: 559-566.
20. US Bureau of the Census. 1960. Historical Statistics of the United States: Colonial Times to 1957. USGPO: Washington.
21. US Council of Economic Advisers. 1998. Economic Report of the President. Washington.
22. US Council of Economic Advisers. 2005. Economic Report of the President. Washington.
23. US House of Representatives, Committee on Science and Technology. 1980. Report: The Food and Drug Administration's Process for Approving New Drugs. USGPO: Washington.